ATRA monotherapy or combined with chemotherapy was the most frequent treatment for TBLR1-RARα APL, observing 2 out of 5 CRs and frequent relapse (including 1 extramedullary). This evidence concerns the gene RARA and acute promyelocytic leukemia.